CancerIQ is a healthcare technology company that uses artificial intelligence and machine learning to help healthcare providers identify patients at high risk of developing cancer, particularly breast cancer, and provide personalized recommendations for prevention and early detection.

Haibo Lu

Feyi Olopade

Moe Alkhafaji

Olufunmilayo Olopade

CancerIQ

Prenosis develops precision medicine tools and implements them in real time for acute care settings, focusing on personalizing healthcare based on individual biology. They leverage their Immunix precision medicine platform and have created the FDA authorized Sepsis ImmunoScore.

Prenosis

About Us
CancerIQ helps providers use genetic information to predict, pre-empt, and prevent disease - starting with cancer. By making is easier to identify patients at risk, offer a genetic evaluation at point of care, and design a tailored cancer prevention plan - we can help healthcare systems get ahead of this costly and emotionally devastating disease.

Why Work with Us?
We have quietly built a market-leading product that patients, providers, and healthcare executives all love. With new funding and new strategic partners, we're on pace for rapid growth. We're a team of clever, scrappy, and mission-driven individuals making a huge impact in cancer prevention - so if you're passionate about healthcare - join our team.

1776 Ventures

Rock Health Capital

HealthX Ventures

Impact Engine

Lightbank

OSF Ventures

McKesson Ventures

Merck Global Health Innovation Fund

Amgen Ventures

CancerIQ believes that everyone, regardless of where they live, deserves the chance to prevent, detect, and treat cancer effectively. Our message this World Cancer Day is clear: the fight against cancer requires more than just digital innovation; it demands equitable approaches to implementation. 

Our impact goes beyond metrics, representing lives saved, families preserved, and communities strengthened. Help us make our mission a reality by joining our team. https://bit.ly/3Ovpzbl

#WorldCancerDay #CloseTheCareGap #AheadOfCancer #PrecisionPrevention

We're incredibly proud to kick off Cancer Prevention Awareness Month with the news that industry leader Diedre Mavin Senatra has joined the team as SVP, Commercial Strategy! She joins CancerIQ at a critical time, as providers must update protocols to meet expanded industry guidelines for cancer risk assessment and genetic testing — and are increasingly seeking out CancerIQ as a solution.

"As a previvor who has lost loved ones to breast cancer, my driving purpose is to expand access to cancer risk assessment and life-saving, genetically informed prevention, treatment and survivorship care. No company does that better than CancerIQ," she said.

With her focus on strategic partnerships, Senatra will work closely with CancerIQ's provider partners to ensure they meet the moment for their patients and get ahead of cancer by improving high-risk patient identification, genetic testing uptake, patient education and long-term medical management. https://lnkd.in/e2uW8Cdd

#CancerPreventionAwarenessMonth #AheadOfCancer #PrecisionPrevention #Previvor

Jessica Hagen at MobiHealthNews, HIMSS Media recently tapped CancerIQ CEO & Co-Founder Feyi Ayodele for a Q&A on the growth of digital health: "The more we learn about the relationship between cancer and our genes and other factors as the science evolves, we should be able to act on that knowledge."

"CancerIQ is a company on a mission to really expand access to the latest innovations in cancer prevention, early detection and treatment. We do that by making sure we're really fully integrating genomic medicine into routine care... We’re truly in the business of interpreting this information, making sure it's getting to patients and is truly in their hands, so that all patient populations can really act on the information, versus just getting tested on its own."

https://bit.ly/47SdNi9 #HIMSS #aheadofcancer #digitalhealth #precisonprevention

KLAS Research interviewed 52 healthcare professionals, and I’m surprised, honored and excited to learn that CancerIQ was named in the final report among the most promising emerging health IT companies of 2024.

This unexpected recognition shows that healthcare leaders recognize that they can't achieve their goals with an EHR alone, and are increasingly seeking out CancerIQ as a solution.

To the anonymous team that heard about CancerIQ and dropped our name to the researcher team at KLAS - thanks for sharing! 

The time is now to use genetic information to get ahead of cancer, and we love that we've been recognized as best in class!

Read more about the report here: https://bit.ly/3OdKwaI

#HITvendors #HITnews #aheadofcancer #precisionprevention

What happens to cancer center volumes when many more breast cancer patients are suddenly eligible for services that are already in high demand? A much larger pool of patients now requires access to genetics given the American Society of Clinical Oncology (ASCO)'s and the Society of Surgical Oncology (SSO)'s recently expanded BRCA1/2 mutation testing recommendations for all breast cancer patients under 65 years old and select patients over age 65.

Importantly, the increased volume of genetic tests introduces a greater demand for genetic counseling, patient education and long-term medical management. As such, providers will need better tools to properly manage their patients. Learn how CancerIQ can help: https://bit.ly/3Hp9iRh

#aheadofcancer #precisionprevention #oncology

The American Cancer Society report lays bare the dire need to broadly screen for cancer predisposition due to genetic, familial, lifestyle and adherence risk, test appropriate patients for genetic mutations at scale, and dramatically increase the number of patients under personalized management. The time is now. And we, along with our incredible health system, lab and screening partners, are working as hard as we can to save lives and reduce the number of patients and families that have to endure the pain that comes along with a late-stage cancer diagnosis.

Metric
Company Name	CancerIQ	Prenosis
Symbol
MSH ID	COM:CANCERIQ	COM:PRENOSIS
Market	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services
Industry	Healthcare & Health Services	Biotechnology
Country	US	US
Stage		Grant
Employee Count	45
Website	canceriq.com	prenosis.com
LinkedIn	cancer-iq-inc-	prenosis
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic		1.15K
Web Traffic Growth		46.92
Valuation
Raised Capital		4.80M

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:CANCERIQ

CancerIQ

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue